STUDIES ON RADIOSENSITIZERS IN THE TREATMENT OF MALIGNANT BRAIN TUMORS Keiji SANO 1 , Takao HOSHINO 1 , Masakatsu NAGAI 1 , Tomio TSUCHIDA 1 , Fumiaki SATO 1 1Dept. of Neurosurgery, Faculty of Medicine, University of Tokyo pp.339-344
Published Date 1967/4/1
DOI https://doi.org/10.11477/mf.1406202198
  • Abstract
  • Look Inside

Bromouridine (5-bromo-2'-deoxyuridine or BUdR), which is known to sensitize bacterial cells or strained tumor cells to irradiation, was proved to be incorpo-rated into the nuclei of human brain tumor cells cultured by trypsinization-monolayer method. This BUdR had neither antimetabolic nor cytocidal effect and only increased the radiosensitivity of the cells which took it up. The uptake of BUdR into the tumor cell nuclei in tissue culture was enhanced by addition of a small amout of antimetabolites such as methotrexate, 5-FU or FUdR. This fact may be explained on a basis that those antimetabolites in-hibited the biosynthesis of thymidine and therefore dividing cells were forced to incorporate newly given thymidine analogue (BUdR) in order to duplicate their DNA.

Based on these facts, the authors have performed Bromouridine-Antimetabolite-Continuous intra-arte-rial infusion-Radiation therapy (BAR therapy). The principle of our method consists of the administration of BUdR (500~1000mg/day) with a small amount of antimetabolite (e.g., methotrexate 1.5~5.0mg/day) by means of continuous intra-arterial (internal carotid) infution for more than one generation time of the tumor cells (3~7 weeks in brain tumors ac-cording to their malignancy) and simultaneous radia-tion therapy (5,000~6,000R tumor dosis). This thera py was applied to 8 brain tumor cases with good therapeutic results. These cases were reviewed and the results and side effects of this therapy were discussed.

Copyright © 1967, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 2185-405X 印刷版ISSN 0006-8969 医学書院